That makes sense, thanks. It does reinforce the effectiveness of Vyrologix, if 2 doses shows survival for not just 28 days but beyond 28 days while placebo patients do pass away. It would explain why the DSMB did not change anything except the 42 days at 75% enrollment. If they felt more doses were needed, they would have recommended a change to the protocol, which they did not. If the vyrologix arm was not showing enough benefit over the placebo arm, they possibly would have called the trial futile and stopped it.